Close Menu

NEW YORK – Trovagene presented data from an ongoing Phase II trial of a metastatic castration-resistant prostate cancer regimen containing its investigational agent onvansertib, abiraterone acetate (Janssen's Zytiga), and prednisone.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.